Max J. Gordon

923 total citations
44 papers, 359 citations indexed

About

Max J. Gordon is a scholar working on Pathology and Forensic Medicine, Genetics and Oncology. According to data from OpenAlex, Max J. Gordon has authored 44 papers receiving a total of 359 indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Pathology and Forensic Medicine, 24 papers in Genetics and 16 papers in Oncology. Recurrent topics in Max J. Gordon's work include Lymphoma Diagnosis and Treatment (26 papers), Chronic Lymphocytic Leukemia Research (24 papers) and CAR-T cell therapy research (9 papers). Max J. Gordon is often cited by papers focused on Lymphoma Diagnosis and Treatment (26 papers), Chronic Lymphocytic Leukemia Research (24 papers) and CAR-T cell therapy research (9 papers). Max J. Gordon collaborates with scholars based in United States, Denmark and Spain. Max J. Gordon's co-authors include Alexey V. Danilov, Stephen E. Spurgeon, Olga V. Danilova, Loretta J. Nastoupil, Mitchell R. Smith, Adam S. Kittai, Jonathon B. Cohen, Daniel O. Persky, Brian T. Hill and Alessandra Ferrajoli and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Max J. Gordon

37 papers receiving 354 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Max J. Gordon United States 11 209 169 120 62 62 44 359
Alfredo Rivas‐Delgado Spain 12 264 1.3× 146 0.9× 184 1.5× 37 0.6× 18 0.3× 27 464
Steven W. Papish United States 10 151 0.7× 91 0.5× 205 1.7× 42 0.7× 17 0.3× 24 438
Marjan Ertault France 9 222 1.1× 84 0.5× 88 0.7× 43 0.7× 63 1.0× 14 306
Bianca Schuhmacher Germany 6 110 0.5× 116 0.7× 85 0.7× 81 1.3× 117 1.9× 9 316
Gaetana Capobianco Italy 10 198 0.9× 90 0.5× 134 1.1× 32 0.5× 15 0.2× 21 281
Diana Libster Israel 9 188 0.9× 70 0.4× 115 1.0× 48 0.8× 78 1.3× 16 301
Manuela Arcamone Italy 8 283 1.4× 108 0.6× 191 1.6× 25 0.4× 22 0.4× 24 357
Fatime Krasniqi Switzerland 8 202 1.0× 69 0.4× 154 1.3× 109 1.8× 119 1.9× 24 363
Federica Quirini Italy 11 372 1.8× 116 0.7× 179 1.5× 35 0.6× 32 0.5× 17 432
Florence Broussais‐Guillaumot France 9 228 1.1× 95 0.6× 153 1.3× 27 0.4× 45 0.7× 14 305

Countries citing papers authored by Max J. Gordon

Since Specialization
Citations

This map shows the geographic impact of Max J. Gordon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Max J. Gordon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Max J. Gordon more than expected).

Fields of papers citing papers by Max J. Gordon

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Max J. Gordon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Max J. Gordon. The network helps show where Max J. Gordon may publish in the future.

Co-authorship network of co-authors of Max J. Gordon

This figure shows the co-authorship network connecting the top 25 collaborators of Max J. Gordon. A scholar is included among the top collaborators of Max J. Gordon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Max J. Gordon. Max J. Gordon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Gordon, Max J., Stefania Pittaluga, Svetlana Pack, et al.. (2025). Enitociclib ( VIP152 ), venetoclax and prednisone in relapsed or refractory aggressive non‐Hodgkin lymphoma. British Journal of Haematology. 208(1). 308–311.
3.
Melani, Christopher, Max J. Gordon, Stefania Pittaluga, et al.. (2024). Abstract PO-008: Phase I/II study of VIP152 (enitociclib), venetoclax, and prednisone (VVIP) in relapsed/refractory (R/R) lymphoid malignancies. Blood Cancer Discovery. 5(3_Supplement). PO–8.
4.
Gordon, Max J., Hui Zhao, Loretta J. Nastoupil, et al.. (2024). Comparison of Comorbidity Models Within a Population-Based Cohort of Older Adults With Non-Hodgkin Lymphoma. JCO Clinical Cancer Informatics. 8(8). e2300223–e2300223. 1 indexed citations
5.
Gordon, Max J., Melissa M. Markofski, Emily C. LaVoy, et al.. (2024). Optimization of mHealth behavioral interventions for patients with chronic lymphocytic leukemia: the HEALTH4CLL study. Journal of Cancer Survivorship. 19(4). 1325–1334. 2 indexed citations
6.
Gordon, Max J., Miloš D. Miljković, Samuel Y. Ng, et al.. (2024). Romidepsin, Azacitidine, Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-Cell Lymphoma. Blood. 144(Supplement 1). 984–984. 2 indexed citations
7.
Gordon, Max J., Jade Jones, Binsah George, et al.. (2023). Long‐term outcomes in patients with chronic lymphocytic leukemia treated with ibrutinib: Focus on hypertension and cardiovascular toxicity. Cancer. 129(14). 2192–2200. 10 indexed citations
8.
Gordon, Max J., et al.. (2022). The CLL comorbidity index in a population-based cohort: a tool for clinical care and research. Blood Advances. 6(8). 2701–2706. 17 indexed citations
9.
Anderson, David E., Alona Zilberberg, Max J. Gordon, et al.. (2020). 1061P TCR and HLA analysis of patients in a phase I/IIa trial of a therapeutic CMV vaccine against recurrent glioblastoma (GBM). Annals of Oncology. 31. S724–S724. 1 indexed citations
10.
Kittai, Adam S., Ying Huang, Max J. Gordon, et al.. (2020). Comorbidities Predict Inferior Survival in Patients Receiving Chimeric Antigen Receptor T Cell Therapy for Diffuse Large B Cell Lymphoma: A Multicenter Analysis. Transplantation and Cellular Therapy. 27(1). 46–52. 37 indexed citations
11.
12.
Gordon, Max J., et al.. (2019). Refractory Autoimmune Cytopenias Treated With Venetoclax. HemaSphere. 3(3). 10 indexed citations
13.
Greenwell, Irl Brian, Ashley D. Staton, Michael J. Lee, et al.. (2018). Complex karyotype in patients with mantle cell lymphoma predicts inferior survival and poor response to intensive induction therapy. Cancer. 124(11). 2306–2315. 34 indexed citations
14.
Greenwell, Irl Brian, Sarah Caulfield, Jeffrey M. Switchenko, et al.. (2017). Outcomes in Mantle Cell Lymphoma for Elderly Patients Undergoing Autologous Stem Cell Transplant in CR1. Biology of Blood and Marrow Transplantation. 23(3). S265–S266. 1 indexed citations
15.
Gordon, Max J., Paul Tardi, Marc Loriaux, et al.. (2016). CPX-351 exhibits potent and direct ex vivo cytotoxicity against AML blasts with enhanced efficacy for cells harboring the FLT3-ITD mutation. Leukemia Research. 53. 39–49. 22 indexed citations
16.
Calzada, Oscar, Jeffrey M. Switchenko, Joseph Maly, et al.. (2016). Deferred treatment as a viable option for selected patients with mantle cell lymphoma.. Journal of Clinical Oncology. 34(15_suppl). 7567–7567. 1 indexed citations
17.
Staton, Ashley D., Irl Brian Greenwell, Jeffrey M. Switchenko, et al.. (2016). Risk Stratification of Untreated Mantle Cell Lymphoma Patients Using MIPI, Ki67 Proliferative Index and Cytogenetics. Blood. 128(22). 1785–1785. 3 indexed citations
18.
Graff, Julie N., Max J. Gordon, & Tomasz M. Beer. (2015). Safety and effectiveness of enzalutamide in men with metastatic, castration-resistant prostate cancer. Expert Opinion on Pharmacotherapy. 16(5). 749–754. 8 indexed citations
19.
Gordon, Max J., J. Carlos Manivel, Edward Y. Cheng, & Keith M. Skubitz. (2014). An Unusual Case of Ewing Sarcoma. Journal of Pediatric Hematology/Oncology. 36(7). e463–e464.
20.
Gordon, Max J., B. A. Peterson, & Keith M. Skubitz. (2014). Lymphoma of the Hands in a Patient With Rheumatoid Arthritis: Case Report. The Journal Of Hand Surgery. 39(4). 728–731. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Alfredo Rivas‐Delgado Breakdown of academic impact, for papers by Steven W. Papish Breakdown of academic impact, for papers by Marjan Ertault Breakdown of academic impact, for papers by Bianca Schuhmacher Breakdown of academic impact, for papers by Gaetana Capobianco Breakdown of academic impact, for papers by Diana Libster Breakdown of academic impact, for papers by Manuela Arcamone Breakdown of academic impact, for papers by Fatime Krasniqi Breakdown of academic impact, for papers by Federica Quirini Breakdown of academic impact, for papers by Florence Broussais‐Guillaumot
Rankless by CCL
2026